Despite the confirmation of these biomarkers’ involvement in lung cancer pathogenesis, we cannot consider the combination of CEA, CYFRA 21-1, NSE, and SAA1 as a panel that would successfully identify lung cancer subtypes and hence be included in the clinical diagnostic scheme of lung cancer patients. The gene discussed is CEACAM5; the disease is lung cancer.